Protagenic Therapeutics Stock Analysis
| PTIXW Stock | USD 0.01 0 34.03% |
Protagenic Therapeutics is fairly valued with Real Value of 0.009416 and Hype Value of 0.009337. The main objective of Protagenic Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Protagenic Therapeutics is worth, separate from its market price. There are two main types of Protagenic Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Protagenic Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Protagenic Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Protagenic Stock trading window is adjusted to America/New York timezone.
Protagenic |
Protagenic Stock Analysis Notes
The company had not issued any dividends in recent years. Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company was founded in 2016 and is based in New York, New York. Protagenic Therapeutics is traded on NASDAQ Exchange in the United States. To find out more about Protagenic Therapeutics contact the company at 212 994 8200 or learn more at https://www.protagenic.com.Protagenic Therapeutics Investment Alerts
| Protagenic Therapeutics is way too risky over 90 days horizon | |
| Protagenic Therapeutics has some characteristics of a very speculative penny stock | |
| Protagenic Therapeutics appears to be risky and price may revert if volatility continues | |
| Protagenic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics has accumulated about 671.09 K in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Protagenic Therapeutics has a frail financial position based on the latest SEC disclosures |
Protagenic Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.21) | |
| Return On Capital Employed | (1.23) | (1.17) | |
| Return On Assets | (1.16) | (1.21) | |
| Return On Equity | (1.36) | (1.30) |
Management Efficiency
The company has return on total asset (ROA) of (0.9017) % which means that it has lost $0.9017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0636) %, meaning that it generated substantial loss on money invested by shareholders. Protagenic Therapeutics' management efficiency ratios could be used to measure how well Protagenic Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.21 in 2024. Return On Capital Employed is likely to climb to -1.17 in 2024. At this time, Protagenic Therapeutics' Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to climb to about 6.4 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 117.2 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.84 | 0.80 | |
| Tangible Book Value Per Share | 0.84 | 0.80 | |
| Enterprise Value Over EBITDA | (0.67) | (0.64) | |
| Price Book Value Ratio | 1.17 | 1.11 | |
| Enterprise Value Multiple | (0.67) | (0.64) | |
| Price Fair Value | 1.17 | 1.11 | |
| Enterprise Value | 3.5 M | 3.3 M |
The management strategies employed by Protagenic Therapeutics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 0.25 | Return On Assets (0.90) | Return On Equity (2.06) |
Technical Drivers
As of the 29th of November, Protagenic Therapeutics holds the Risk Adjusted Performance of 0.0664, coefficient of variation of 1351.99, and Semi Deviation of 18.23. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protagenic Therapeutics, as well as the relationship between them. Please check Protagenic Therapeutics variance and potential upside to decide if Protagenic Therapeutics is priced some-what accurately, providing market reflects its current price of 0.0095 per share. As Protagenic Therapeutics appears to be a penny stock we also advise to check out its total risk alpha numbers.Protagenic Therapeutics Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Protagenic Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Protagenic Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Protagenic Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protagenic Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protagenic Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protagenic Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Musci Raymond over a month ago Acquisition by Musci Raymond of 1758 shares of Protagenic Therapeutics at 2.09 subject to Rule 16b-3 | ||
Musci Raymond over a month ago Acquisition by Musci Raymond of 569 shares of Protagenic Therapeutics at 2.07 subject to Rule 16b-3 | ||
Ekizian Gregory over two months ago Disposition of 75000 shares by Ekizian Gregory of Protagenic Therapeutics at 1.0 subject to Rule 16b-3 | ||
Brilliant Digital Entertainment Inc over three months ago Acquisition by Brilliant Digital Entertainment Inc of 758621 shares of Protagenic Therapeutics at 2.9 subject to Rule 16b-3 | ||
Musci Raymond over six months ago Acquisition by Musci Raymond of tradable shares of Protagenic Therapeutics at 2.0 subject to Rule 16b-3 | ||
Robert Stein over six months ago Acquisition by Robert Stein of 200000 shares of Protagenic Therapeutics at 1.75 subject to Rule 16b-3 | ||
Garo Armen over six months ago Acquisition by Garo Armen of 500000 shares of Protagenic Therapeutics at 1.25 subject to Rule 16b-3 |
Protagenic Therapeutics Predictive Daily Indicators
Protagenic Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Protagenic Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Protagenic Therapeutics Forecast Models
Protagenic Therapeutics' time-series forecasting models are one of many Protagenic Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Protagenic Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Protagenic Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Protagenic Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Protagenic shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Protagenic Therapeutics. By using and applying Protagenic Stock analysis, traders can create a robust methodology for identifying Protagenic entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.59) | (0.62) | |
| Operating Profit Margin | (0.64) | (0.67) | |
| Net Loss | (0.57) | (0.60) | |
| Gross Profit Margin | (0.08) | (0.07) |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Protagenic Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.